226 related articles for article (PubMed ID: 11924798)
1. Use of genetically modified mouse models for evaluation of carcinogenic risk: considerations for the laboratory animal scientist.
Recio L; Everitt J
Comp Med; 2001 Oct; 51(5):399-405. PubMed ID: 11924798
[TBL] [Abstract][Full Text] [Related]
2. The utility of genetically modified mouse assays for identifying human carcinogens: a basic understanding and path forward. The Alternatives to Carcinogenicity Testing Committee ILSI HESI.
MacDonald J; French JE; Gerson RJ; Goodman J; Inoue T; Jacobs A; Kasper P; Keller D; Lavin A; Long G; McCullough B; Sistare FD; Storer R; van der Laan JW
Toxicol Sci; 2004 Feb; 77(2):188-94. PubMed ID: 14657512
[TBL] [Abstract][Full Text] [Related]
3. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the Xpa-deficient transgenic mouse model for short-term carcinogenicity testing: 9-month studies with haloperidol, reserpine, phenacetin, and D-mannitol.
Lina BA; Woutersen RA; Bruijntjes JP; van Benthem J; van den Berg JA; Monbaliu J; Thoolen BJ; Beems RB; van Kreijl CF
Toxicol Pathol; 2004; 32(2):192-201. PubMed ID: 15200157
[TBL] [Abstract][Full Text] [Related]
5. The transgenic mouse assay as an alternative test method for regulatory carcinogenicity studies--implications for REACH.
Wells MY; Williams ES
Regul Toxicol Pharmacol; 2009 Mar; 53(2):150-5. PubMed ID: 19126422
[TBL] [Abstract][Full Text] [Related]
6. Detection of genotoxic and non-genotoxic carcinogens in Xpc(-/-)p53(+/-) mice.
Melis JP; Speksnijder EN; Kuiper RV; Salvatori DC; Schaap MM; Maas S; Robinson J; Verhoef A; van Benthem J; Luijten M; van Steeg H
Toxicol Appl Pharmacol; 2013 Jan; 266(2):289-97. PubMed ID: 23153559
[TBL] [Abstract][Full Text] [Related]
7. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
Gaylor DW
Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
[TBL] [Abstract][Full Text] [Related]
8. [The use of biotechnological recombinant-mice in biological safety research].
Inoue T
Eisei Shikenjo Hokoku; 1996; (114):1-12. PubMed ID: 9037857
[TBL] [Abstract][Full Text] [Related]
9. Genetically altered mouse models for identifying carcinogens.
Tennant RW; Stasiewicz S; Mennear J; French JE; Spalding JW
IARC Sci Publ; 1999; (146):123-50. PubMed ID: 10353386
[No Abstract] [Full Text] [Related]
10. The program for phenotyping of genetically modified animals at AstraZeneca.
Berg AL; Bohlooly-Y M
Exp Toxicol Pathol; 2006 Jul; 57(5-6):383-4. PubMed ID: 16709449
[TBL] [Abstract][Full Text] [Related]
11. Finding transcriptomics biomarkers for in vivo identification of (non-)genotoxic carcinogens using wild-type and Xpa/p53 mutant mouse models.
Jonker MJ; Bruning O; van Iterson M; Schaap MM; van der Hoeven TV; Vrieling H; Beems RB; de Vries A; van Steeg H; Breit TM; Luijten M
Carcinogenesis; 2009 Oct; 30(10):1805-12. PubMed ID: 19696161
[TBL] [Abstract][Full Text] [Related]
12. Use of transgenic animals for carcinogenicity testing: considerations and implications for risk assessment.
Gulezian D; Jacobson-Kram D; McCullough CB; Olson H; Recio L; Robinson D; Storer R; Tennant R; Ward JM; Neumann DA
Toxicol Pathol; 2000; 28(3):482-99. PubMed ID: 10862569
[TBL] [Abstract][Full Text] [Related]
13. Use of rasH2 transgenic mice for carcinogenesis testing of medical implants.
Palazzi X; Kergozien-Framery S
Exp Toxicol Pathol; 2009 Sep; 61(5):433-41. PubMed ID: 19062264
[TBL] [Abstract][Full Text] [Related]
14. Investigations of clofibrate in alternative carcinogenicity models.
Santostefano MJ; Hoivik DJ; Miller RT
Int J Toxicol; 2005; 24(5):285-8. PubMed ID: 16257848
[No Abstract] [Full Text] [Related]
15. Evaluation on carcinogenicity of chemicals using transgenic mice.
Mitsumori K
Toxicology; 2002 Dec; 181-182():241-4. PubMed ID: 12505318
[TBL] [Abstract][Full Text] [Related]
16. Relationship between UV-induced mutant p53 patches and skin tumours, analysed by mutation spectra and by induction kinetics in various DNA-repair-deficient mice.
Rebel H; Kram N; Westerman A; Banus S; van Kranen HJ; de Gruijl FR
Carcinogenesis; 2005 Dec; 26(12):2123-30. PubMed ID: 16051635
[TBL] [Abstract][Full Text] [Related]
17. Behavioural phenotyping of transgenic mice.
Brown RE
Can J Exp Psychol; 2007 Dec; 61(4):328-44. PubMed ID: 18266509
[TBL] [Abstract][Full Text] [Related]
18. Studies evaluating the utility of N-methyl-N-nitrosourea as a positive control in carcinogenicity studies in the p53+/- mouse.
Hoivik DJ; Allen JS; Wall HG; Nold JB; Miller RT; Santostefano MJ
Int J Toxicol; 2005; 24(5):349-56. PubMed ID: 16257854
[TBL] [Abstract][Full Text] [Related]
19. Mouse models of abdominal aortic aneurysms.
Daugherty A; Cassis LA
Arterioscler Thromb Vasc Biol; 2004 Mar; 24(3):429-34. PubMed ID: 14739119
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the levels of enzymes involved in drug metabolism between transgenic or gene-knockout and the parental mice.
Ariyoshi N; Imaoka S; Nakayama K; Takahashi Y; Fujita K; Funae Y; Kamataki T
Toxicol Pathol; 2001; 29 Suppl():161-72. PubMed ID: 11695553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
